CN110312737A - Mmp9抑制剂及其在预防或治疗色素脱失病症中的用途 - Google Patents

Mmp9抑制剂及其在预防或治疗色素脱失病症中的用途 Download PDF

Info

Publication number
CN110312737A
CN110312737A CN201780078081.9A CN201780078081A CN110312737A CN 110312737 A CN110312737 A CN 110312737A CN 201780078081 A CN201780078081 A CN 201780078081A CN 110312737 A CN110312737 A CN 110312737A
Authority
CN
China
Prior art keywords
depigmentation
mmp9
inhibitor
expression
cadherin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078081.9A
Other languages
English (en)
Chinese (zh)
Inventor
卡地亚·博尼法斯
朱利安·塞纳斯查尔
内斯里那·鲍科赫度尼
克莱芒·雅克曼
弗朗西斯-格扎维埃·贝尔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
France National Medical Association Of Health And Research
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Original Assignee
France National Medical Association Of Health And Research
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by France National Medical Association Of Health And Research, Centre Hospitalier Universitaire de Bordeaux, Universite de Bordeaux filed Critical France National Medical Association Of Health And Research
Publication of CN110312737A publication Critical patent/CN110312737A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201780078081.9A 2016-12-16 2017-12-15 Mmp9抑制剂及其在预防或治疗色素脱失病症中的用途 Pending CN110312737A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306719 2016-12-16
EP16306719.2 2016-12-16
PCT/EP2017/083182 WO2018109222A1 (en) 2016-12-16 2017-12-15 Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder

Publications (1)

Publication Number Publication Date
CN110312737A true CN110312737A (zh) 2019-10-08

Family

ID=57680192

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078081.9A Pending CN110312737A (zh) 2016-12-16 2017-12-15 Mmp9抑制剂及其在预防或治疗色素脱失病症中的用途

Country Status (6)

Country Link
US (1) US10894837B2 (https=)
EP (1) EP3555138A1 (https=)
JP (1) JP7141397B2 (https=)
CN (1) CN110312737A (https=)
BR (1) BR112019012253A2 (https=)
WO (1) WO2018109222A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061351A1 (en) * 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
US20240285497A1 (en) 2021-02-26 2024-08-29 National University Corporation Kobe University Method for evaluating an ability of a test sample to trigger a foreign body reaction in the skin, a method for screening a substance having an ability to inhibit a foreign body reaction in the skin, and an agent for inhibiting a foreign body reaction in the skin
WO2024028417A1 (en) * 2022-08-03 2024-02-08 Institut National de la Santé et de la Recherche Médicale New composition for the treatment and/or prevention of vitiligo
CN119236080A (zh) * 2024-09-29 2025-01-03 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种医药组合物在制备用于治疗多发性硬化药物中的应用
CN120945015B (zh) * 2025-10-17 2025-12-23 潍坊市人民医院(潍坊市公共卫生临床中心、潍坊市职业病医院) 一种适用于黑色素瘤基因检测的脱色素方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037513A1 (en) * 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
WO2016023972A1 (en) * 2014-08-13 2016-02-18 Calypso Biotech Sa Antibodies specific for mmp9

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59708838D1 (de) 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20040053876A1 (en) 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US8101348B2 (en) 2002-07-10 2012-01-24 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. RNA-interference by single-stranded RNA molecules
EP2395996A1 (en) * 2009-02-13 2011-12-21 Indiana University Research and Technology Corporation Compounds and methods for inhibiting mmp2 and mmp9
EP2608809B1 (en) 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
WO2013130078A1 (en) 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
FR3015986A1 (fr) 2013-12-30 2015-07-03 Lvmh Rech Aptameres inhibiteurs de l'activite enzymatique de la proteine mmp-9
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037513A1 (en) * 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
WO2016023972A1 (en) * 2014-08-13 2016-02-18 Calypso Biotech Sa Antibodies specific for mmp9

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEREK C. MARSHALL等: ""Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer"", 《PLOS ONE》 *
LAURENCE GOFFIN等: ""Anti-MMP-9 Antibody：A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis"", 《INFLAMMATORY BOWEL DISEASES》 *

Also Published As

Publication number Publication date
JP2020504719A (ja) 2020-02-13
US20190359730A1 (en) 2019-11-28
EP3555138A1 (en) 2019-10-23
JP7141397B2 (ja) 2022-09-22
BR112019012253A2 (pt) 2020-01-28
US10894837B2 (en) 2021-01-19
WO2018109222A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
Vinaik et al. NLRP3 inflammasome activity is required for wound healing after burns
JP7141397B2 (ja) Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用
OuYang et al. Interleukin-4 stimulates proliferation of endometriotic stromal cells
Maretzky et al. ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis
Huber et al. TNFα-mediated induction of PAI-1 restricts invasion of HTR-8/SVneo trophoblast cells
Gellersen et al. Human endometrial stromal cell-trophoblast interactions: mutual stimulation of chemotactic migration and promigratory roles of cell surface molecules CD82 and CEACAM1
Kopecki et al. Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita
Dufour et al. IL-17A dissociates inflammation from fibrogenesis in systemic sclerosis
Jain et al. Endothelin-1 Induces Endoplasmic Reticulum Stress by Activating the PLC-IP3 Pathway: Implications for Placental Pathophysiology in Preeclampsia
Schneider et al. Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion
Gschwandtner et al. Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor
Beltrami-Moreira et al. Redundancy of IL-1 isoform signaling and its implications for arterial remodeling
Zhang et al. XCL 1‐XCR 1 pathway promotes trophoblast invasion at maternal‐fetal interface by inducing MMP‐2/MMP‐9 activity
TAKEI‐TANIGUCHI et al. Interleukin‐17‐and protease‐activated receptor 2‐mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes
Estrada-Gutierrez et al. Increased expression of matrix metalloproteinase-1 in systemic vessels of preeclamptic women: a critical mediator of vascular dysfunction
EP2565275A1 (en) Method of treatment of vascular complications using modulators of TRX and TRXNIP
Tancharoen et al. Cleavage of host cytokeratin-6 by lysine-specific gingipain induces gingival inflammation in periodontitis patients
Baston-Büst et al. CXCL1 expression in human decidua in vitro is mediated via the MAPK signalling cascade
Pringle et al. New light on early post-implantation pregnancy in the mouse: roles for insulin-like growth factor-II (IGF-II)?
ES2895628T3 (es) Inhibidores de GSK3B en el tratamiento de trastornos de hipopigmentación
EP3336175B1 (en) Three-dimensional model of depigmenting disorder
ES2905438T3 (es) Proteínas de la vía de señalización de WNT y usos de las mismas en el diagnóstico y tratamiento de trastornos de hipopigmentación
US20210268068A1 (en) Methods and pharmaceutical compositions for the treatment of tissue lesions
US9551710B2 (en) Signaling molecule involved in ultraviolet damage to skin
JP2022501388A (ja) 関節リウマチにおけるｐｔｐｒｓ及びプロテオグリカン

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination